Why the study?
Statin therapy may delay carotid intima-media thickness progression, but long-term studies evaluating its effect in children are scarce.
Does atorvastatin treatment reduce carotid intima-media thickness in children with severe dyslipidemia?
Does atorvastatin treatment reduce carotid intima-media thickness in children with severe dyslipidemia?
Atorvastatin therapy in children with severe dyslipidemia significantly improves lipid profiles and may halt cIMT progression, though cIMT reduction was not statistically significant.
Atorvastatin was associated with cIMT changes in dyslipidemic children; hypothesis-generating and requires randomized confirmation before practice change.
Carotid intima-media thickness (cIMT) has been proposed as an early marker of subclinical atherosclerosis in high risk children. Children with heterozygous familial hypercholesterolemia have greater cIMT than matched healthy controls or their unaffected siblings. Statin therapy may delay the progression of cIMT, although long-term studies in children are scarce. We evaluated the effect of atorvastatin treatment on cIMT in children with dyslipidemia. We studied 81 children/adolescents, 27 with severe dyslipidemia (low-density lipoprotein cholesterol [LDL-C] ≥190 mg/dL) and 54 sex- and age-matched healthy controls; LDL-C ≤ 130 mg/dL and lipoprotein (a), Lp(a), ≤30 mg/dL. In the children with dyslipidemia, cIMT was measured twice, before and on treatment (18.2 ± 7.7 months). Anthropometric data, a full lipid profile, liver, kidney, and thyroid function were evaluated. Males with dyslipidemia had a greater cIMT than male controls after adjustment for other factors ( P = .049). In addition, a nonstatistically significant decrease in cIMT was observed after treatment ( P = .261). Treatment with atorvastatin resulted in a significantly improved lipid profile. Females with dyslipidemia had a significantly thinner cIMT than males. Children with normal and high Lp(a) levels had similar cIMT values. In conclusion, treatment with atorvastatin had a beneficial effect on the lipid profile and cIMT progression in children with severe dyslipidemia.
No takes yet. Share an insight, caveat, or question.
Karapostolakis et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: